PT  - JOURNAL ARTICLE
AU  - Rainwater-Lovett, Kaitlin
AU  - Redd, John T.
AU  - Stewart, Miles A.
AU  - Elías Calles, Natalia
AU  - Cluff, Tyler
AU  - Fang, Mike
AU  - Panaggio, Mark J.
AU  - Lambrou, Anastasia S.
AU  - Thornhill, Jonathan K.
AU  - Bradburne, Christopher
AU  - Imbriale, Samuel
AU  - Freeman, Jeffrey D.
AU  - Anderson, Michael
AU  - Kadlec, Robert
TI  - Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
AID  - 10.1101/2021.04.08.21254705
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.08.21254705
4099  - http://medrxiv.org/content/early/2021/08/13/2021.04.08.21254705.short
4100  - http://medrxiv.org/content/early/2021/08/13/2021.04.08.21254705.full
AB  - Background Monoclonal antibodies (mAbs) against SARS-CoV-2 are a promising treatment for limiting the progression of COVID-19 and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadvantaged populations.Methods Electronic health records were reviewed from SARS-CoV-2 patients at a single medical center in the United States that initiated mAb infusions in January 2021 with the support of the U.S. Department of Health and Human Services’ National Disaster Medical System. Patients who received mAbs were compared to untreated patients from the time period before mAb availability who met eligibility criteria for mAb treatment. We used logistic regression to measure the effect of mAb treatment on the risk of hospitalization or emergency department (E.D.) visit within 30 days of laboratory-confirmed COVID-19.Results Of 598 COVID-19 patients, 270 (45%) received bamlanivimab and 328 (55%) were untreated. Two hundred and thirty-one patients (39%) were Hispanic. Among treated patients, 5/270 (1.9%) presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39/328 (12%) untreated patients (p<0.001). After adjusting for age, gender, and comorbidities, the risk of E.D. visit or hospitalization was 82% lower in mAb-treated patients compared to untreated patients (95% confidence interval [CI]: 66%-94%).Conclusions In this diverse, real-world COVID-19 patient population, mAb treatment significantly decreased the risk of subsequent E.D. visit or hospitalization. Broader treatment with mAbs, including in disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all populations in the United States to ensure health equity.Summary In a diverse, real-world COVID-19 patient population, treatment with monoclonal antibodies significantly decreased the risk of subsequent emergency department visit or hospitalization within 30 days of a positive SARS-CoV-2 viral test.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll authors have completed the ICMJE uniform disclosure form: all authors had financial support from the U.S. Department of Health and Human Services, Office of the Assistant Secretary of Preparedness and Response for the submitted work. The authors or their institutions did not receive payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical support activity was conducted as part of the Office of the Assistant Secretary of Preparedness and Response's public health response to the COVID-19 pandemic and at the request of the host medical center. Under the Department of Health and Human Services Office of Health Research Protection guidelines, it was judged a non-research COVID-19 response. The Johns Hopkins University Applied Physics Laboratory and the medical center concurred with a non-research determination.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data was used from electronic medical records as part of process improvement and is not publicly available.